FindTrial
Sign In

Infanrix™ hexa

BIOLOGICAL8 trials

Sponsors

GlaxoSmithKline, MCM Vaccines B.V., Merck Sharp & Dohme LLC

Conditions

Acellular PertussisBacterial InfectionsDiphtheriaHaemophilus Influenzae Type bHepatitis BInfections, MeningococcalMeningococcal VaccinesNeisseria Meningitidis

Phase 3

Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
CompletedNCT00322335
GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis
Start: 2006-05-31End: 2010-09-30Updated: 2016-10-20
Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine
CompletedNCT00508261
GlaxoSmithKlineInfections, Meningococcal
Start: 2007-08-01End: 2008-10-27Updated: 2019-01-24
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines
CompletedNCT01144663
GlaxoSmithKlineInfections, Meningococcal, Meningococcal Vaccines
Start: 2010-07-01End: 2013-09-10Updated: 2020-12-31
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
CompletedNCT01341639
MCM Vaccines B.V.Bacterial Infections, Virus Diseases
Start: 2011-05-26End: 2013-03-13Updated: 2019-04-30
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
CompletedNCT01480258
MCM Vaccines B.V.Bacterial Infections, Virus Diseases
Start: 2011-11-23End: 2013-10-09Updated: 2019-04-02
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
CompletedNCT04031846
Merck Sharp & Dohme LLCPneumococcal Infections
Start: 2019-09-04End: 2021-08-05Updated: 2023-07-28

Phase 4

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children
CompletedNCT00611559
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Hepatitis B +2
Start: 2008-02-14End: 2008-06-25Updated: 2018-06-06
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
CompletedNCT00753649
GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3
Start: 2008-09-23End: 2013-03-12Updated: 2019-11-27

Related Papers

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
2023-04-2520 citations
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants: Results of an Open, Randomized Trial.
2018-07-011 citations
Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
2017-04-0110 citations
A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.
2017-02-0122 citations
A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.
2016-06-1828 citations
Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants
Vaccine2015-02-1810 citations